Skip to main content

Advertisement

SpringerLink
Log in

First CAR-T therapy to target BCMA gets FDA nod

  • News in Brief
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

First CAR-T therapy to target BCMA gets FDA nod. Nat Biotechnol 39, 531 (2021). https://doi.org/10.1038/s41587-021-00929-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-021-00929-0

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation